Study uncovers the role of DNA repair in preserving egg quality

NewsGuard 100/100 Score

A Monash University study has uncovered the role DNA repair plays in preserving egg quality, offering hope for women whose eggs may be damaged through treatments such as radiation and chemotherapy.

The study, led by Monash Biomedicine Discovery Institute (BDI), found that when the cell death pathway is inhibited in oocytes (eggs) these eggs are capable of repairing severe DNA damage sufficiently to produce healthy offspring.

By exposing female mice deficient in TAp63, a key regulator of cell death in eggs, to various doses of gamma irradiation, it was observed that the oocytes will rapidly repair the DNA damage to maintain oocyte quality and female fertility.

Findings published in the medical journal PNAS, led by Associate Professor Karla Hutt and Dr Jessica Stringer, outline that among the many types of DNA damage, double-strand breaks (DSBs) are the most harmful and promote chromosome rearrangements and mutations and lead to genetic instability if the DSBs are repaired incorrectly.

Women are born with their lifetime supply of eggs, which makes them one of the longest living cells in the human body. This means that eggs are exposed to years of external and internal stressors that may damage the DNA and contribute to the reduced oocyte quality in women over 35 years of age. We have identified the DNA repair pathway that oocytes use to repair DSBs and confirmed that repair is efficient and accurate to prevent mutations in offspring generated from these eggs."

Karla Hutt, Associate Professor, Monash University

Unlike other cells in the human body, oocytes have an extremely low tolerance for DNA damage and will activate cell death pathways when exposed to the stressors of things like radiation, chemotherapeutic drugs, and environmental toxins (e.g. pollution, pesticides). Blocking oocyte death is being actively investigated as one of the most promising methods to preserve future fertility and endocrine health in female cancer patients.

"Cancer treatments work by causing DNA damage, and a common side effect for female patients is ovarian damage which can lead to infertility and loss of endocrine function (such as early onset menopause). This study provides a fundamental step towards developing a truly effective fertility preservation strategy for female cancer patients and has important implications for prolonging women's fertile lifespan," Dr Stringer said.

With survival rates for many common cancers now exceeding 80 per cent, and an estimated population of 14 million female cancer survivors world-wide, there is a clear need to develop innovative approaches to protect the ovary from damage during anti-cancer treatment.

Moreover, in Australia, 20 per cent of women have their first child after 35 years of age, an age at which fertility plummets and rates of miscarriage and birth defects increase dramatically. This striking maternal age effect is due to loss of oocyte quality and possibly diminished DNA repair capacity.

Source:
Journal reference:

Stringer, J.M., et al. (2020) Oocytes can efficiently repair DNA double-strand breaks to restore genetic integrity and protect offspring health. PNAS. doi.org/10.1073/pnas.2001124117.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels